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Challenges and Opportunities for
Early Career Cardiologists/Faculty DirectorsTochi M. Okwuosa, DO,* Ana Barac, MD, PHDyF rom 1935 to 2013, cardiovascular diseases andcancer have been the 2 leading causes of deathsuch that, in 2010, heart disease and cancer
accounted for 46% of all deaths in the United States
(1). Notwithstanding, owing to the success gained in
ﬁnding treatments and cures for various cancers,
overall cancer survival rate has skyrocketed, with
about 14.5 million cancer survivors in the United
States (1). Ironically, the clinical success of cancer
therapy is attenuated by comorbid cardiovascular dis-
eases as major complications (next to second malig-
nancy) of intense oncology treatment.
To usher the patient safely through cancer therapy
while tempering cardiovascular disease as a com-
peting cause of morbidity and mortality, a clinical
discipline—called cardio-oncology or onco-cardiology—
has evolved. Practice in this discipline commonly
involves a specialist in cardiovascular disease, often
with additional expertise in heart failure and/or car-
diovascular imaging, and also includes oncologists
and the oncology care team, psychosocial providers,
as well as primary care providers (Figure 1).
The exclusion of cancer patients from cardiovascular
clinical trials and heart disease patients from oncology
investigations has resulted in a paucity of data to direct
clinical decision-making in many cardio-oncology pa-
tients. The oncologist may hesitate to give life-saving,
potentially cardiotoxic therapy for fear of an adverse
cardiac outcome, and the cardiologist may have difﬁ-
culty in understanding appropriate measures on the
basis of a patient’s cancer-related comorbidities and
prognosis. Consequently, the cardio-oncologist plays
the pivotal role of intersecting the 2 specialties, seeking
to establish a comprehensive plan to address theFrom the *Cardio-Oncology Services, Rush University Medical Center,
Chicago, Illinois; and the yCardio-oncology Program, Medstar Heart and
Vascular Institute, Georgetown University, Washington, DC.comorbidities, while achieving necessary life-saving
therapies. With the growing patient need, a number
of cardio-oncology clinical programs are emerging
across the United States, adding to previously estab-
lished cardio-oncology services localized in a few pri-
mary cancer institutions (2). Early career cardiologists
actively participate and often serve as a driving force in
many of these programs. In this paper, we summarize
some of the challenges that junior faculty may face and
discuss opportunities for learning and growth.
ESTABLISHING A
CARDIO-ONCOLOGY PROGRAM
In cardio-oncology—as with any other program—insti-
tutional support is paramount to achieving success,
but is not always easy to achieve. The lack of academic
and administrative mentorship presents a major chal-
lenge. Its reasons include: novelty of this ﬁeld, a
shortage of evidence-based clinical standards, a lack of
opportunities for education and training, and a limited
awareness among local oncology and cardiology spe-
cialists about the need for cardio-oncology services (2).
Active participation in growing cardio-oncology net-
works may provide critical clues on potential solutions
for these challenges and open horizons for growth.
INSTITUTIONAL SUPPORT AND
COORDINATION OF CARE
Some approaches to facilitate institutional support
for the junior (or any) faculty member attempting to
build a cardio-oncology program are listed in Table 1.
In general, an institutional administration (including
cardiology) that appreciates cardio-oncology as a
cardiovascular subspecialty is more inclined to dis-
burse funds and resources to establish a cardiology
service dedicated to oncology patients. Examples of
needed support include:




























The various responsibilities of a cardio-oncologist are diagramed, showing the constant feedback and interactive process to effect
integrated patient care. Modiﬁed with permission from Okwuosa TM, Akhter N, Williams KA, DeCara JM. Building a cardio-oncology program in
a small to medium-sized, nonprimary cancer center, academic hospital in the USA: challenges and pitfalls. Future Cardiol 2015;11:1–8.
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11941. Clinical staff, such as a medical assistants, clinic
nurses, and physician extenders (nurse practi-
tioners/physician assistants), for:
a. Coordination of cardio-oncology appointments
and other cancer care, including chemotherapy,
radiology studies, oncology and surgical ap-
pointments, and so on;
b. Timely scheduling of (serial) cardiac imaging
and/or laboratory studies with prompt care on
the basis of results;
c. Keeping abreast of changes in cancer treatment
plans and/or changes in cardiovascular status
including updates to all team members;
d. Patient education and engagement;
e. Coordinated documentation of medication adjust-
ments and dose updates, including cancer treat-
ments, for the purposes of cardio-oncology; and
f. Enhancing clinical ﬂow where physician ex-
tenders could see more stable or return patients,
freeing up some time for the cardio-oncologist
to incorporate more complex patients into their
clinic schedule.
2. Time to engage hospital staff and the community
to grow a comprehensive program, which includes:
a. Participating in oncology tumor board conferences;
b. Partnering with other cardiology and oncology
team members to develop population-focused
approaches for subgroups of patients, such ascancer survivorship clinics or patients under-
going treatment with vascular endothelial
growth factor–pathway inhibitors;
c. Training cardiology staff and technicians on
newer diagnostic data and techniques, such as
development of cardio-oncology–speciﬁc imag-
ing pathways; and
d. Providing awareness about the program within
and around the local health care organization
through presentations, workshops, and partici-
pation in existing programs.
3. Resources to establish a cardio-oncology database
for informative and research purposes.
4. Time for professional education: includes
educating hospital staff and trainees, as well as
attending professional conferences with speciﬁc
emphasis on development of the program.
LOCATION OF AMBULATORY
CARDIO-ONCOLOGY CLINIC
Establishing the location of the clinic—in a cancer or
cardiovascular center—is 1 of the key decisions to
ensure the success of a cardio-oncology program and
is dependent on a number of factors, including hos-
pital administration and funding, proximity of the
cardiovascular to the oncology clinics, interactions
between both faculty members and staff, stafﬁng
TABLE 1 Approaches to Facilitate Institutional Support for Cardio-Oncology
Process Measures Methods
Creating awareness  Educating and establishing cognizance of the necessity
for cardio-oncology within the entire hospital, including
other physicians,* physician extenders,† nurses, and
administrative staff including the hospital leaders and
decision makers
 May involve multiple presentations on the necessity for
and embodiment of cardio-oncology at different
forums, including hospital grand rounds, various
administrative committees, hospital symposia,
and so on
 The onco-cardiologist should be prepared to attend (and
even seek) meetings with leadership and be prepared
with relevant highlights on what necessitates this ﬁeld
Patient education  Seminars, community events, symposia, and so on
 Informs patients to be attentive to the downstream
effects of their cancer therapy
 Patients are generally interested in learning how to care
for their health, and may seek out the onco-cardiologist
especially for this reason
Hospital staff education  Includes teaching and providing educational materials
on cardio-oncology; cardiovascular risks of cancer
therapeutic agents; diagnoses, management, and
treatment; when to refer to cardio-oncology; as well as
updates in the published data
 Lectures on various cardio-oncology topics should be
provided to medical trainees and house staff‡
Organizing a comprehensive
program
 That should involve exchange of patient information
with discussions and updates on change in clinical
status§
Input at oncology forums  Includes tumor board conferences and oncology grand
rounds
 Makes for more comprehensive decision making on
cancer therapies and overall patient care; oncologists
value this sort of inputk
Providing evidence of growth  Eventually necessary to convince administration of the
need for cardio-oncology¶
 Alerts administration to the need for resources and/or
the fact that already provided resources are being
applied in a constructive manner
Providing outcome data  Providing data on better patient outcomes as a result of
the establishment of a cardio-oncology clinic would
provide the ultimate driving force for establishment and
growth of the program
*Oncologists, cardiologists, primary care physicians. †Nurse practitioners (NPs)/physician assistants (PAs).
‡Including medical students, residents, fellows, other cardiologists, oncologists, general practitioners, and
medical support staff including oncology nurses, NPs, and PAs. §Should include the onco-cardiologist, the
oncologist, and their support staff, particularly the nurses, NPs and PAs, pharmacist, social services (psychosocial
oncology, case managers, and social workers), rehabilitation services (such as cardiac rehabilitation, physical
therapy, and so on), nutritionist, and palliative care; creation of algorithms for patient education, management,
and referrals with special cancer programs such as the cancer survivorship clinic, and so on. kIn turn, attendance at
these tumor board conferences and oncology grand rounds helps provide some perspective with respect to pa-
tient management from an oncology standpoint, while informing the onco-cardiologist on (previously unknown)
characteristics of existing cancer therapies in addition to expectations for newer ones. ¶Demonstration of growth
of cardiovascular services, such as echocardiography or cardiac magnetic resonance imaging referrals, linked to
cardio-oncology is generally encouraging to any institution. Reprinted with permission from Okwuosa TM, Akhter
N, Williams KA, DeCara JM. Building a cardio-oncology program in a small to medium-sized, nonprimary cancer
center, academic hospital in the USA: challenges and pitfalls. Future Cardiol 2015;11:1–8.
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1195methods, available process measures, and location of
the cardiovascular imaging center(s). The pros and
cons of a cardio-oncology clinic location in either a
cancer or cardiovascular center are shown in Table 2.
Essential to making a decision on location is the
knowledge that a cardio-oncology clinic must lend
itself well to interdisciplinary communication and
provider accessibility for patients.
Depending on its goals and objectives, some cardio-
oncology programs have dedicated inpatient con-
sultative services. These services are possible in
institutions with 2 or more practicing cardio-
oncologists, particularly with support staff. Con-
versely, an institution with only 1 practicing
cardio-oncologist and not much support staff could
adopt an approach where the general cardiology ser-
vice sees and consults on the cancer inpatient, with/
without some input from the cardio-oncologist, with
subsequent cardio-oncology outpatient follow-up.
RESEARCH AND MENTORSHIP
Another key component of establishing a successful
cardio-oncology program is conduction of meaningful
research, which consequently enhances recognition
and growth of the program. Finding a cardio-oncology
research mentor is a major difﬁculty faced by the
young faculty, but can be overcome by a motivated
junior investigator. One could ﬁnd a mentor in
oncology and another in cardiology (e.g., in cardio-
vascular imaging or heart failure) and then generate
project ideas with potential for growth through the
collaboration. Another possibility is to identify a
mentor in 1 of the few major cancer centers in the
country with an already established cardio-oncology
program (2), which raises the concern of a long-
distance mentor-mentee relationship with less con-
tact and therefore fewer accomplishedwork. However,
this plan could offer an advantage with fostering
interinstitutional collaborations and growth of this
fascinating ﬁeld.
Limited data in this nascent ﬁeld leave a myriad of
unanswered questions about the relationship among
cancer, cancer therapies, and the heart, with a wide-
open ﬁeld of research. At the same time, funding in
less-established ﬁelds such as this one can pose spe-
ciﬁc challenges. A recent publication summarizing
the recommendations of the 2013 National Heart,
Lung, and Blood Institute and National Cancer In-
stitute workshop on cancer treatment–related car-
diotoxicity provides valuable insight into current
scientiﬁc priorities and an important resource for
person(s) considering development of a cardio-
oncology research project (3).FUTURE OPPORTUNITIES FOR
CARDIO-ONCOLOGY PROGRAMS AND
CAREER GROWTH
Many cardio-oncology programs are being developed
across the United States by relatively young junior
cardiologists who take on the task of engaging
hospital/institutional administration for time and
resources to facilitate program success. In response to
the challenges, some of which are summarized in the
TABLE 2 Pros and Cons of a Cardio-Oncology Clinic Location in a Cardiovascular Versus
Cancer Center
Cardio-Oncology Clinic in
Cardiovascular Center Cardio-Oncology Clinic in Cancer Center
Pros  Support staff that are familiar
with the spectrum of cardiovas-
cular disease
 Patient and provider proximity to
cardiovascular services such as
ECG and echocardiography
services
 Easy patient access to cardio-
oncology
 Capacity for more comprehen-
sive patient care
 Improved contact with the on-
cologists for immediate ques-
tions, consultations, and tumor
board opinions, and a generally
more inclusive care of the can-
cer patient
Cons  Loss of exclusivity to the special
needs of the cancer patient
 Lack of awareness by the oncol-
ogists about a special cardiology
service dedicated to serving their
patients
 Less spontaneous consultations
and interactions between oncol-
ogists and serving cardiologist(s)
which may hamper the evolution
of a comprehensive service
 Limited access to cardiovascu-
lar studies such as ECG, echo-
cardiography, and stress tests
(depending on size and funding
in institution)
 Less availability of staff trained
in performing ECGs/other car-
diac studies, and can answer
cardiac questions/educate pa-
tients on cardiac care
Circumvent
the cons
 The cardiologist should be pro-
active in fostering relationships
with the oncologist and the
oncology team
 Attendance—and contribution
to—tumor board conferences and
oncology grand rounds with the
goal of integrating the cardio-
oncologist into the day-to-day
practices of the oncology team
 Additional training of the cardi-
ology clinic staff, including
knowledge of common chemo-
therapies with relevance to car-
diovascular health, need for more
frequent monitoring, psychoso-
cial needs of the cancer patient,
and so on
 ECG, and possibly, echocardi-
ography machine(s)/services in
the cancer center to effect
more efﬁcient cardiovascular
diagnosis and care of these
patients
 Institute effective transporta-
tion between the cardiac
imaging center and oncology
clinic
 Train oncology staff in cardio-
vascular care and assistance
(including performing ECGs)
ECG ¼ electrocardiogram.
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1196previous text, there has been a call for platforms
that allow for knowledge exchange and inter-
disciplinary education within the ﬁeld of cardio-
oncology. The American College of Cardiology’s
Cardio-Oncology Working Group organized the ﬁrst
Cardio-Oncology Intensive at the 64th Annual Sci-
entiﬁc Sessions (ACC.15), which brought specialists
and subspecialists from across a number of disci-
plines to discuss advances in diverse aspects of
clinical care, research, and cardio-oncology program
development. A survey noted in a recent publication
by this group demonstrated a widespread apprecia-
tion of cardiovascular concerns in cancer patients
and survivors, identifying at the same time a num-
ber of critical barriers for the development of
specialized services (2). The newly formed ACC
Cardio-Oncology Member Section aims to serve as a
professional home for the growing number of spe-
cialists in this ﬁeld. Its success and the ability to
advance the future of cardio-oncology programs will
critically depend on the contribution of all, and in
particular, of early career members focused on
advancing this ﬁeld within their institutions and
nationally.
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1197RESPONSE: Cancer and the Heart:
A Fortuitous Union Between Oncology
and Cardiology
Edward T.H. Yeh, MD
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
E-mail: etyeh@mdanderson.orgWhen I was asked to build a department of cardiology in a
major cancer center 15 years ago, I was often askedwhether
my department specialized in caring for “cancer of the
heart,” andwhy there is a need for a cardiologist in a cancer
center. For decades, cardiologists and oncologists have
worked in different spheres, attending to their favorite
maladies. However, it has become increasingly apparent
that cancer patients would beneﬁt from the expert care of
both cardiologists and oncologists, because heart disease
and cancer often coexist in the same patient. Furthermore,
cancer therapy frequently causes either short- or long-term
cardiovascular complications. Many chemotherapy drugs
are known to cause cardiomyopathy, thromboembolic
disease, ischemic heart disease, blood pressure alterations,
and rhythm disorders (1). Radiation therapy accelerates
atherosclerosis and causes valvular and pericardial heart
diseases (2). Thus, cardiovascular consultations are often
needed during active cancer therapy or in cancer survivors.
In MD Anderson Cancer Center, the department of cardi-
ology employs 12 full-time cardiologists to provide
comprehensive cardiac care to our cancer patients. How-
ever, in the majority of noncancer hospitals, cardiac
consultation for cancer patients is often given by a single
provider or by referral to outside institutions. Given the
success of modern cancer therapy and the sheer increase in
the number of cancer survivors, there is a tremendous
opportunity for cardiologist to enter this burgeoning ﬁeld
called “onco-cardiology” or “cardio-oncology.”
Drs. Okwuosa and Barac have written a thoughtful
piece on the challenges and opportunities for early career
cardiologists to enter into this new subspecialty. Theycarefully outline the need to obtain institutional support
and the strategy for growing a comprehensive program.
Many of these recommendations are excellent, but need to
be individualized. Clearly, the most important ingredient
for success is persistence and the willingness to provide
prompt and high-quality advice to our oncologic col-
leagues. Another hurdle for the young cardiologists is the
lack of knowledge base in this new ﬁeld, because cancer
has been an exclusion criterion for most of the cardiology
trials. We have organized 3 international conferences in
cancer and the heart with the mission to educate our next-
generation onco-cardiologists. In addition, we have
developed algorithms based on the practice patterns of
cardiologists in our department, called the MD Anderson
Practice, from which 11 video modules are available (3).
These resources should serve as a good starting point for
the burgeoning onco-cardiologist.
Finally, the interface between cardiology and oncology
also provides an excellent opportunity for basic and clin-
ical research. A good example is the discovery of a new
paradigm for anthracycline-induced cardiomyopathy that
may lead to new strategy for prevention (4). Multiple
clinical trials are currently in progress to determine
whether chemotherapy-induced cardiotoxicity can be
predicted by biomarkers and ameliorated with cardiac
medications. Furthermore, with the increasing number of
targeted therapies that interfere with prosurvival signaling
in the heart, we also can learn valuable lessons from our
patients about cardiovascular biology. In summary, the
future success of onco-cardiology is only limited by our
imagination.RE F E RENCE S1. Yeh ETH, Bickford C. Cardiovascular complica-
tions of cancer therapy: incidence, pathogenesis,
diagnosis and management. J Am Coll Cardiol
2009;53:2231–47.2. Darby S, Cutter D, Boerma M, et al. Radiation-
related heart disease: current knowledge and
future prospects. Int J Radiation Oncology Biol
2010;76:656–65.
3. MD Anderson Cancer Center. Cancer and
the heart programs. Available at: www.
cancerandtheheart.org. Accessed July 18, 2015.4. Zhang S, Liu X, Bawa-Khalfe T, et al. Identi-
ﬁcation of the molecular basis of doxorubicin-
induced cardiotoxicity. Nat Med 2012;18:
1639–42.
